Shasqi Presents Initial Data Validating Approach of Click Chemistry Activated Oncology Therapeutics at ESMO Congress 2021

Excerpt from the Press Release:

— SQ3370, a novel investigational product that activates doxorubicin at the tumor site while minimizing systemic exposure, is the first click chemistry-based treatment to be used in humans

— Initial Phase 1 data suggest more than 50 times greater exposure of doxorubicin in tumor versus plasma

— No observed dose-limiting toxicity to date when SQ3370 is administered at doses up to four times higher than conventional doxorubicin

— Nonclinical and clinical data support Shasqi continuing Phase 1 SQ3370 dose escalation

SAN FRANCISCO–(BUSINESS WIRE)–Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) platform, presented interim data from its Phase 1 clinical study of SQ3370 in advanced sarcomas and other solid tumors, as well as additional non-clinical data at the European Society for Medical Oncology (ESMO) Congress, being held virtually on September 16-21, 2021.

The interim Phase 1 clinical data were presented at the developmental therapeutics virtual poster session:

• Abstract Title: Early pharmacokinetic data from a Phase I study of SQ3370 (NCT04106492) in patients with advanced solid tumors provides proof-of-concept for the click chemistry-based CAPAC platform
• Presentation Number: 547P
• Virtual Poster Session Title: Developmental therapeutics
• Link to full poster details here.

The non-clinical data were presented at the basic science virtual poster session:

• Abstract Title: Click Activated Protodrugs Against Cancer (CAPAC) Platform Enhances the Safety, Pharmacokinetics, and Antitumor Efficacy of Cancer Therapies in vivo
• Presentation Number: 9P
• Virtual Poster Session Title: Basic science
• Link to full poster details here.

“These early data from our Phase 1 study of SQ3370 provide initial validation for our click chemistry-based platform in humans with an encouraging safety profile,” said José M. Mejía Oneto, M.D., Ph.D., Founder and CEO of Shasqi. “Cytotoxic agents remain standard of care for many cancers because they are effective at killing tumor cells. Our platform is designed to enhance the therapeutic benefit of these agents while minimizing toxicity. With this early validation of our platform, we can continue to advance SQ3370 and explore the application of our technology beyond chemotherapies to other standard of care cancer therapies with a limited therapeutic window.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release